Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · IEX Real-Time Price · USD
46.37
0.53 (1.16%)
May 27, 2022 10:38 AM EDT - Market open
Market Cap3.25B
Revenue (ttm)331.95M
Net Income (ttm)-470.20M
Shares Out70.05M
EPS (ttm)-6.87
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume80,688
Open45.85
Previous Close45.84
Day's Range45.30 - 46.48
52-Week Range45.20 - 105.99
Beta1.58
AnalystsBuy
Price Target131.39 (+183.4%)
Earnings DateMay 5, 2022

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysacc...

IndustryBiotechnology
IPO DateJan 31, 2014
CEOEmil Kakkis
Employees1,119
Stock ExchangeNASDAQ
Ticker SymbolRARE
Full Company Profile

Financial Performance

In 2021, RARE's revenue was $351.41 million, an increase of 29.66% compared to the previous year's $271.03 million. Losses were -$454.03 million, 143.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for RARE stock is "Buy." The 12-month stock price forecast is 131.39, which is an increase of 183.35% from the latest price.

Price Target
$131.39
(183.35% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate

Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.

1 week ago - Zacks Investment Research

Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates

Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.

2 weeks ago - Zacks Investment Research

Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -24.43% and 5.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare a...

3 weeks ago - GlobeNewsWire

Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference

NOVATO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seriou...

3 weeks ago - GlobeNewsWire

Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update

NOVATO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serio...

4 weeks ago - GlobeNewsWire

Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report

NOVATO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serio...

1 month ago - GlobeNewsWire

Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

Physician researcher and biopharmaceutical executive to join R&D Committee Physician researcher and biopharmaceutical executive to join R&D Committee

1 month ago - GlobeNewsWire

Ultragenyx (RARE) Begins Dosing in Pivotal Study on Setrusumab

Ultragenyx (RARE) doses the first patient in a pivotal phase II/III study evaluating setrusumab (UX143) for the treatment of osteogenesis imperfecta.

1 month ago - Zacks Investment Research

Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment ...

Global study will evaluate UX143 in pediatric and young adult patients ages 5 to

1 month ago - GlobeNewsWire

Ultragenyx to Participate in the Cowen Health Care Conference

NOVATO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri...

2 months ago - GlobeNewsWire

Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates

Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.

3 months ago - Zacks Investment Research

Ultragenyx (RARE) Reports Q4 Loss, Lags Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -35.61% and 0.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

2021 total revenue of $351.4 million and 2021 Crysvita® revenue in Ultragenyx territories 1 of $192.6 million

3 months ago - GlobeNewsWire

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2021 Financial Results and Corporate Update

NOVATO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seriou...

3 months ago - GlobeNewsWire

Regeneron (REGN) Collaborates With Ultragenyx for Evkeeza

Regeneron (REGN) teams up with Ultragenyx Pharmaceutical to commercialize and distribute Evkeeza (evinacumab) outside the United States.

Other symbols:REGN
4 months ago - Zacks Investment Research

Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvita® in Ultragenyx Territories* And Do...

Preliminary 2021 Crysvita revenue in Ultragenyx territories of $191 million to $193 million and Dojolvi revenue of $38 million to $40 million

4 months ago - GlobeNewsWire

Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference

NOVATO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serio...

4 months ago - GlobeNewsWire

Ultragenyx to Present at 40th Annual JP Morgan Healthcare Conference

NOVATO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serio...

4 months ago - GlobeNewsWire

Why Is Ultragenyx (RARE) Down 11.4% Since Last Earnings Report?

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Ultragenyx (RARE) Begins Dosing in Phase I/II Study of UX053

Ultragenyx (RARE) doses the first patient in a phase I/II study evaluating its investigational mRNA candidate, UX053, for treating glycogen storage disease type III.

5 months ago - Zacks Investment Research

GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & Gala

Overall GTX-102 program update on track for the end of 2021 Overall GTX-102 program update on track for the end of 2021

5 months ago - GlobeNewsWire

Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of G...

NOVATO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seriou...

5 months ago - GlobeNewsWire